No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
98 |
4. Check minimum number of eventsNone |
98 |
5. Include endpointsNone |
98 |
6. Filter based on genotype QC (FinnGen only) |
98 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E87
- Name in latin
- Incrementum voluminis liquoris
Similar endpoints
↥List of similar endpoints to
Fluid overload
based on the number of shared cases.
Similar with more cases:
- Other disorders of fluid, electrolyte and acid-base balance
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 582 | 293 | 287 |
| Only index persons | 524 | 263 | 261 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 69.82 | 72.88 | 66.78 |
| Only index persons | 69.84 | 72.88 | 66.78 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 98 | 46 | 52 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 63.74 | 68.23 | 59.78 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 88
- Matched controls
- 879
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E87.7
ICD-10 Finland
Fluid overload
+∞
126.7
88
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
247.0
33.2
32
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
35.2
32.1
42
22
C03CA01
ATC
furosemide; systemic
17.6
31.0
70
159
TK800
NOMESCO Finland
Hemodialysis
117.4
30.1
31
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
73.8
30.0
33
7
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
55.7
26.0
30
8
I50.9
ICD-10 Finland
Heart failure, unspecified
14.4
24.1
46
62
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
162.5
23.9
24
*
N18.8
ICD-10 Finland
Other chronic renal failure
37.0
23.8
30
12
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
+∞
21.8
20
*
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
136.0
20.6
21
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
9.8
20.2
50
104
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
10.9
19.1
41
65
TPX10
NOMESCO Finland
Implantation of vascular injection port
85.0
18.6
20
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
8.7
18.3
70
271
A12AA04
ATC
calcium carbonate; oral
54.2
18.2
21
5
N18.0
ICD-10 Finland
End-stage renal disease
+∞
17.2
16
*
OAB74
NOMESCO Finland
Nutritional guidance related to treatment and rehabilitation for medical condition
207.8
17.1
17
*
A10AC01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)
17.1
16.8
27
22
B03XA02
ATC
darbepoetin alfa; parenteral
30.1
16.0
21
9
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
18.9
15.7
24
17
J18.9
ICD-10 Finland
Pneumonia, unspecified
7.0
15.3
47
123
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
8.8
15.2
36
64
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
51.8
14.7
17
*
N17.9
ICD-10 Finland
Acute renal failure, unspecified
23.0
14.2
20
11
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
14.5
14.1
24
22
A10AE04
ATC
insulin glargine; parenteral
10.9
14.0
28
36
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
48.1
13.7
16
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
9.8
13.6
29
42
A11CC03
ATC
alfacalcidol; systemic
27.8
13.5
18
8
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
14.4
13.5
23
21
SPAT1262
SPAT
Handing over of treatment supplies
7.0
13.4
38
86
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
59.5
13.3
15
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
59.5
13.3
15
*
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
16.8
13.3
21
16
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.3
13.0
31
54
E87.5
ICD-10 Finland
Hyperkalaemia
+∞
12.8
12
*
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
150.6
12.8
13
*
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
18.2
12.5
19
13
SPAT1148
SPAT
Treatment of chronic ulcer or burn
7.3
12.4
33
67
215
Kela drug reimbursment
Diabetes, non-insulin-treated
5.8
12.4
44
130
103
Kela drug reimbursment
Diabetes, insulin-treated
5.5
12.2
46
146
N19
ICD-10 Finland
Unspecified kidney failure
24.0
11.6
16
8
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
10.0
11.3
23
30
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
32.8
11.1
14
5
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
6.2
11.1
33
77
A46
ICD-10 Finland
Erysipelas
6.8
11.0
30
62
M04AA01
ATC
allopurinol; systemic
6.6
11.0
31
67
C07AB07
ATC
bisoprolol; oral
4.9
11.0
64
308
XF600
NOMESCO Finland
Bloodpressure measurement
10.1
11.0
22
28
M10.9
ICD-10 Finland
Gout, unspecified
11.4
10.7
20
22
V03AE01
ATC
polystyrene sulfonate; oral
124.2
10.7
11
*
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
124.2
10.7
11
*
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
12.4
10.7
19
19
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
30.1
10.1
13
5
A10AE05
ATC
insulin detemir; parenteral
13.7
10.1
17
15
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
17.8
9.9
15
10
Z94.0
ICD-10 Finland
Kidney transplant status
62.1
9.9
11
*
137
Kela drug reimbursment
Uraemia requiring dialysis
62.1
9.9
11
*
L04AD02
ATC
tacrolimus; systemic (calcineurin inhibitors)
62.1
9.9
11
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
8.3
9.8
22
34
I50.0
ICD-10 Finland
Congestive heart failure
8.3
9.8
22
34
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
4.9
9.7
37
113
L04AA06
ATC
mycophenolic acid; systemic
34.3
9.7
12
*
S97
ICPC
Chronic ulcer skin
11.0
9.6
18
20
J01FF01
ATC
clindamycin; systemic
4.6
9.5
41
141
D64.9
ICD-10 Finland
Anaemia, unspecified
7.1
9.5
24
44
B01AB10
ATC
tinzaparin; parenteral
10.5
9.4
18
21
R50.9
ICD-10 Finland
Fever, unspecified
5.3
9.3
31
81
C08CA01
ATC
amlodipine; oral
4.2
9.3
50
208
Z49.2
ICD-10 Finland
Other dialysis
41.4
9.3
11
*
WX204
NOMESCO Finland
Axillary plexus blockaced
12.7
9.2
16
15
R06.0
ICD-10 Finland
Dyspnoea
4.4
9.1
41
146
A10AA02
ATC
NA
16.3
9.0
14
10
A10AB01
ATC
insulin (human); parenteral (insulins and analog. for injection, fast-acting)
16.3
9.0
14
10
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
4.9
8.9
33
96
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
7.2
8.9
22
39
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
55.7
8.9
10
*
A10AA01
ATC
NA
22.8
8.7
12
6
127
Kela drug reimbursment
Transplant complication
31.0
8.7
11
*
H04AA01
ATC
glucagon; nasal, parenteral
31.0
8.7
11
*
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
99.2
8.6
9
*
V03AE02
ATC
sevelamer; oral
99.2
8.6
9
*
JAK10
NOMESCO Finland
Laparotomy and insertion of peritoneal dialysis catheter
99.2
8.6
9
*
A10BH05
ATC
linagliptin; oral
16.7
8.5
13
9
V03AE03
ATC
lanthanum carbonate; oral
+∞
8.5
8
*
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
37.1
8.3
10
*
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
24.8
8.2
11
5
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.9
8.2
45
187
I25.1
ICD-10 Finland
Atherosclerotic heart disease
4.5
8.2
32
98
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
8.9
8.1
17
23
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
12.5
8.1
14
13
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
7.5
8.1
19
31
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
6.9
8.0
20
36
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.9
8.0
41
161
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
10.4
7.9
15
17
H02AB06
ATC
prednisolone; systemic
3.7
7.9
56
282
X59
ICD-10 Finland
Exposure to unspecified factor
4.4
7.8
31
96
QXB99
NOMESCO Finland
Other procedure to treat skin wound, unspecified location
27.8
7.8
10
*
TPH07
NOMESCO Finland
Cathetrisation of artery
5.9
7.7
22
47
WX892
NOMESCO Finland
Monitored bed care
6.8
7.6
19
34
EBA15
NOMESCO Finland
Extraction of large number of teeth
10.9
7.6
14
15
NHQ40
NOMESCO Finland
Amputation of toe
87.1
7.5
8
*
196
Kela drug reimbursment
Paricalcitol and cinacalcet
+∞
7.4
7
*
KA9AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
7.4
7
*
H05BX01
ATC
cinacalcet; oral
+∞
7.4
7
*
B03XA03
ATC
methoxy polyethylene glycol-epoetin beta; parenteral
+∞
7.4
7
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.8
7.2
37
142
WW500
NOMESCO Finland
Blood transfusion
9.6
7.1
14
17
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
15.5
7.1
11
8
I48.0
ICD-10 Finland
Paroxysmal atrial fibrillation
12.4
7.0
12
11
J01MA12
ATC
levofloxacin; systemic
4.0
7.0
32
111
H3603, E103
ICD-10 Finland
NA
43.5
6.9
8
*
B05DB
ATC
Hypertonic solutions
43.5
6.9
8
*
B05DA
ATC
Isotonic solutions
43.5
6.9
8
*
JN4AD
NOMESCO Finland
Body CT examination
7.3
6.9
16
26
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
4.2
6.8
28
88
T89
ICPC
Diabetes insulin dependent
11.4
6.8
12
12
C03DA01
ATC
spironolactone; oral
5.2
6.7
21
50
J01MA14
ATC
moxifloxacin; systemic
5.4
6.7
20
45
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
7.0
6.7
16
27
A10AD01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate- or long-acting comb. with fast-acting)
15.9
6.6
10
7
E10.1
ICD-10 Finland
Type 1 diabetes mellitus, With ketoacidosis
75.1
6.5
7
*
E10.8
ICD-10 Finland
Type 1 diabetes mellitus, With unspecified complications
75.1
6.5
7
*
E86
ICD-10 Finland
Volume depletion
75.1
6.5
7
*
OAB73
NOMESCO Finland
Prevention and treatment of malnutrition
75.1
6.5
7
*
A02BC02
ATC
pantoprazole; systemic
3.5
6.5
68
433
R60.9
ICD-10 Finland
Oedema, unspecified
12.4
6.5
11
10
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
12.4
6.5
11
10
T90
ICPC
Diabetes non-insulin dependent
3.7
6.5
33
123
L03.1
ICD-10 Finland
Cellulitis of other parts of limb
19.8
6.4
9
5
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.7
6.4
18
38
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.5
6.4
23
64
WX213
NOMESCO Finland
Lower leg blockade
+∞
6.3
6
*
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
+∞
6.3
6
*
PB1AC
NOMESCO Finland
Angiography of upper extremity with X-ray
+∞
6.3
6
*
M10.3
ICD-10 Finland
Gout due to impairment of renal function
+∞
6.3
6
*
QXA20
NOMESCO Finland
Skin abrasion, unspecified location
+∞
6.3
6
*
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
6.3
6
*
ZX108
NOMESCO Finland
Inhalation
+∞
6.3
6
*
N25.8
ICD-10 Finland
Other disorders resulting from impaired renal tubular function
+∞
6.3
6
*
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
4.2
6.3
25
76
A41.9
ICD-10 Finland
Sepsis, unspecified
13.9
6.3
10
8
R4110
NOMESCO Finland
Physiotherapy
3.5
6.2
35
141
SPAT1255
SPAT
Intravenous administration of medicine
8.3
6.2
13
18
B01AA03
ATC
warfarin; systemic
3.7
6.2
30
109
C09AA02
ATC
enalapril; systemic
3.9
6.1
27
90
SPAT1222
SPAT
Counselling/guidance promoting independent living
3.9
6.1
27
90
JN3AD
NOMESCO Finland
Abdominal CT examination
6.1
6.1
16
31
I50.1
ICD-10 Finland
Left ventricular failure
9.1
6.1
12
15
WX002
NOMESCO Finland
Sedation and analgesia
3.8
6.1
27
91
C07AB02
ATC
metoprolol; systemic
3.7
6.0
29
104
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
16.5
6.0
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
32
13
36.07
47.04
15.6
1.7
4.9
4.8
kpa
0.22
32
13
33
16
30.59
45.44
7.5
2.1
14.7
15.9
%
—
21
8
41
33
20.64
44.73
18.4
4.8
23.4
25.3
mmol/l
1.55
41
33
29
11
37.02
43.42
5.3
1.8
1.3
1.6
mmol/l
0.56
29
11
40
43
15.03
36.23
9.6
3.0
2.3
2.1
mmol/l
0.07
30
33
49
73
12.42
35.18
10.2
3.3
—
—
—
0
0
30
29
14.47
28.60
9.8
2.8
24.4
24.4
mmol/l
0.02
22
24
22
12
23.35
28.19
2.1
1.2
232.0
296.2
u/ml
—
17
5
27
23
15.82
27.71
2.9
1.5
—
—
—
0
0
54
118
8.97
27.20
4.5
2.0
—
—
—
0
0
21
13
20.29
25.31
2.0
1.2
—
—
—
0
0
21
14
18.82
24.39
2.6
1.1
—
—
—
0
0
38
63
9.22
24.13
41.9
2.7
1.2
1.2
mmol/l
2.09
38
55
23
21
14.00
22.41
3.1
1.5
—
—
—
0
0
59
172
7.11
21.45
3.8
2.0
3.3
3.0
mg/l
0.65
52
148
33
54
8.71
20.95
2.6
1.6
—
—
—
0
0
19
15
15.47
20.02
3.4
1.7
—
—
—
0
0
17
12
16.93
18.96
5.4
4.4
62.9
60.3
%
0.32
17
12
17
12
16.93
18.96
3.7
1.2
—
—
—
0
0
83
366
9.28
18.48
43.8
6.4
1.2
1.2
mmol/l
2.25
65
312
21
23
11.35
18.00
3.2
1.4
—
—
—
0
0
65
239
6.11
17.40
5.8
3.2
9881.1
1231.3
ng/l
3.25
58
207
16
12
15.74
17.21
5.3
4.4
5.0
3.8
e9/l
0.91
16
12
62
229
5.65
16.22
12.3
2.6
0.7
0.5
e6/l
0.45
54
170
70
291
5.92
15.74
13.2
3.6
81.8
38.1
ng/l
1.29
63
214
37
91
5.93
15.41
3.8
1.8
—
—
—
0
0
36
88
5.89
15.06
3.9
1.8
—
—
—
0
0
25
43
7.46
14.85
2.0
1.4
—
—
—
0
0
69
295
5.52
14.67
14.3
2.9
—
—
—
0
0
14
12
13.44
13.83
1.4
1.6
—
—
—
0
0
58
224
4.89
13.80
12.9
3.6
69.9
6.5
mg/mmol
2.56
52
129
14
13
12.40
13.16
2.6
1.3
—
—
—
0
0
62
262
4.72
12.88
7.4
2.7
65.5
56.6
u/l
0.50
57
238
47
162
4.65
12.77
2.5
1.6
1.2
1.5
mg/l
0.54
40
125
44
146
4.65
12.52
3.1
1.8
1725.4
1258.8
nmol/l
0.90
31
106
16
6
31.45
12.50
3.8
1.3
—
—
—
0
0
13
12
12.34
12.22
2.7
1.3
—
—
—
0
0
16
8
23.53
11.57
3.9
1.3
—
—
—
0
0
17
25
8.02
11.42
2.4
2.8
—
—
—
0
0
14
16
10.04
11.40
2.6
1.3
—
—
—
0
0
31
85
4.87
11.05
7.4
12.0
2.4
1.5
mmol/l
0.25
19
69
43
153
4.23
10.92
3.8
2.4
—
—
—
0
0
15
20
8.67
10.88
2.2
2.1
99.1
85.3
%
1.02
15
20
19
37
6.13
9.81
8.3
3.2
126.6
128.7
g/l
0.11
19
37
67
342
4.03
9.81
7.3
4.4
—
—
—
0
0
14
9
17.86
9.35
2.6
1.4
—
—
—
0
0
69
381
3.74
8.51
9.6
3.3
0.0
0.0
estimate
0.00
30
69
8
0
+∞
8.45
8.0
0.0
30.8
—
ug/min
—
8
0
8
0
+∞
8.45
10.5
0.0
—
—
—
0
0
68
376
3.64
8.29
11.1
4.2
0.0
0.0
estimate
0.00
34
71
68
379
3.59
8.12
9.6
3.3
0.0
0.0
estimate
0.00
34
73
12
18
7.46
7.80
2.5
2.8
226.5
196.9
%
0.27
12
18
14
25
6.37
7.79
2.2
1.1
—
—
—
0
0
48
222
3.28
7.70
10.2
3.8
0.0
0.0
estimate
0.00
15
67
15
30
5.72
7.45
17.4
2.9
25.5
24.9
mmol/l
0.20
15
30
7
0
+∞
7.38
3.4
0.0
—
—
—
0
0
55
281
3.18
7.37
2.5
1.9
104.6
97.9
pmol/l
0.31
31
141
15
32
5.35
6.95
6.5
2.0
1.7
1.2
%
0.59
15
32
11
9
13.57
6.76
1.5
1.2
—
—
—
0
0
11
18
6.76
6.58
1.5
1.6
—
—
—
0
0
56
306
2.94
6.40
9.9
3.4
—
—
—
0
0
18
50
4.18
6.09
3.8
2.4
28.5
74.1
ml/min/173m2
5.47
13
19
11
20
6.07
5.95
4.0
2.9
—
—
—
0
0
10
17
6.44
5.75
3.8
2.5
—
—
—
0
0
11
21
5.77
5.67
1.4
2.0
—
—
—
0
0
13
30
4.84
5.48
10.5
3.4
46.3
54.1
%
0.38
13
30
10
18
6.07
5.44
2.6
1.3
—
—
—
0
0
10
18
6.07
5.44
2.6
1.3
—
—
—
0
0
5
0
+∞
5.25
1.2
0.0
—
—
—
0
0
5
0
+∞
5.25
5.0
0.0
—
—
—
0
0
5
0
+∞
5.25
3.6
0.0
444.0
—
umol/l
—
5
0
12
28
4.74
4.98
18.2
3.4
25.1
25.0
mmol/l
0.04
12
28
28
119
2.89
4.89
4.8
2.5
3.9
1.7
e6/l
0.40
15
63
8
8
10.75
4.61
1.3
1.0
—
—
—
0
0
29
137
2.59
4.08
4.7
2.3
0.7
1.0
e6/l
0.51
16
81
7
7
10.64
4.08
1.3
1.9
—
—
—
0
0
9
15
6.48
3.91
1.1
1.2
—
—
—
0
0
6
5
12.65
3.81
7.5
7.8
613.0
662.8
nmol/l
—
6
5
6
5
12.65
3.81
10.2
9.8
1319.8
1084.0
nmol/l
—
6
5
6
6
10.54
3.54
3.5
2.5
—
—
—
0
0
75
567
2.38
3.31
5.1
3.8
14.8
14.9
pmol/l
0.14
70
515
6
8
7.89
3.10
1.5
1.3
93.2
173.7
u/l
—
6
8
6
9
7.01
2.91
1.5
1.3
—
—
—
0
0
0
68
0.00
2.73
0.0
1.7
—
—
—
0
0
86
718
2.62
2.60
80.5
12.8
48.1
79.7
ml/min/173m2
10.68
81
594
11
39
3.05
2.57
3.8
1.7
—
—
—
0
0
8
22
3.86
2.42
1.4
1.2
—
—
—
0
0
7
17
4.35
2.40
3.3
1.4
—
—
—
0
0
5
8
6.51
2.40
1.2
1.4
—
—
—
0
0
5
9
5.78
2.24
1.6
1.9
—
—
—
0
0
5
9
5.78
2.24
1.6
1.9
—
—
—
0
0
5
9
5.78
2.24
1.6
1.9
—
—
—
0
0
29
173
1.96
2.23
1.5
1.3
9.3
1.0
u/ml
0.44
11
40
9
30
3.20
2.21
3.7
1.3
—
—
—
0
0
9
32
2.99
2.06
1.9
1.8
—
—
—
0
0
6
16
3.92
1.96
2.2
1.2
—
—
—
0
0
5
11
4.72
1.96
3.4
1.4
—
—
—
0
0
5
11
4.72
1.96
3.4
1.4
—
—
—
0
0
5
11
4.72
1.96
3.4
1.4
—
—
—
0
0
5
11
4.72
1.96
3.4
1.4
—
—
—
0
0
5
11
4.72
1.96
3.4
1.4
—
—
—
0
0
5
12
4.33
1.84
3.4
1.3
—
—
—
0
0
5
12
4.33
1.84
1.0
1.2
—
—
—
0
0
6
18
3.48
1.77
1.3
1.1
—
—
—
0
0
57
453
1.62
1.50
4.9
2.8
—
—
—
0
0
5
18
2.87
1.30
1.0
1.1
—
—
—
0
0
15
236
0.57
1.18
3.1
4.5
27.4
20.1
%
—
5
110
5
20
2.58
1.16
1.0
2.0
—
11275.8
—
0
5
7
33
2.21
1.08
1.3
1.3
—
—
—
0
0
12
69
1.84
1.02
2.9
2.1
40.8
5.0
ug/l
0.45
12
63
18
124
1.55
0.82
1.1
1.3
40.2
20.4
iu/ml
—
5
40
5
91
0.53
0.71
1.4
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
2.7
—
0
7
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
1.1
—
0
5
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
14
118
1.22
0.20
1.1
1.3
26.4
10.1
u/ml
—
7
48
9
81
1.12
0.15
1.7
2.5
—
—
—
0
0
8
73
1.10
0.08
1.6
2.5
—
—
—
0
0
74
743
0.98
0.00
8.3
4.6
6.8
6.0
mmol/l
2.40
69
666
10
104
0.96
0.00
1.7
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
9
99
0.90
0.00
20.1
6.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
3.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
7
79
0.88
0.00
4.4
2.5
16.8
13.9
nmol/l
—
7
72
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
3.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_FLUIDOVER and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_FLUIDOVER | 3.281 [1.98, 5.44] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.135 |
During the follow-up period (1.1.1998 — 31.12.2019), 103 out of 212 females with E4_FLUIDOVER died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_FLUIDOVER | 6.861 [3.77, 12.48] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.098 |
During the follow-up period (1.1.1998 — 31.12.2019), 127 out of 212 males with E4_FLUIDOVER died.
Mortality risk
Mortality risk for people of age
years, who have E4_FLUIDOVER.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.229% | 1.763% |
| 5 | 1.508% | 9.368% |
| 10 | 4.476% | 22.161% |
| 15 | 8.006% | 39.888% |
| 20 | 13.834% | 56.64% |
Relationships between endpoints
↥Index endpoint: E4_FLUIDOVER – Fluid overload
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data